Opinion

Video

Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions

Author(s):

Ryan Haumschild, PharmD, MS, MBAMarwan Fakih, MD

Medical experts discuss additional factors for sequencing therapies such as FTD/TPI plus bevacizumab, fruquintinib, and regorafenib, and identify future research needs for optimizing therapy sequences.

Video content above is prompted by the following:

  1. What additional factors do you consider when determining the most effective sequence of these therapies (FTD/TPI plus bevacizumab, fruquintinib, regorafenib)?
  2. What future research is needed to better understand the optimal sequencing of these therapies?
Related Videos
1 KOL is featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Rachel Dalthorp, MD
1 KOL is featured in this series.
Dr Peter Schmid
5 KOLs are featured in this series.
Related Content
Frontline d-VRd and frontline d-VTd produced deep, durable responses in patients with transplant-eligible multiple myeloma. | Image credit: Катерина Євтехова - stock.adobe.com
September 25th 2024

Daratumumab Quadruplets Show Durable Outcomes in Transplant-Eligible Multiple Myeloma

Rose McNulty
Daratumumab plus VRd and frontline daratumumab plus VTd produced deep, durable responses in patients with transplant-eligible multiple myeloma in updates to the PERSEUS and CASSIOPEIA trials, respectively.
Managed Care Cast logo
July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
EMA logo | Image Credit: Ricochet64 - stock.adobe.com
September 25th 2024

CHMP Recommends Mirvetuximab Soravtansine for FRα+ Ovarian Cancer

Ashling Wahner
The European Medicines Agency's (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has recommended the marketing authorization of mirvetuximab soravtansine (Elahere; AbbVie) for folate receptor alpha–positive (FRα+), platinum-resistant epithelial ovarian cancer.
Managed Care Cast
May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi
In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.
Rivaroxaban | Image: Janssen
September 25th 2024

Korean Study Finds DOAC Use “Seems Effective” in Patients With MPNs

Mary Caffrey
A study based on a decade's worth of Korean insurance data found that use of direct oral anticoagulants (DOACs) to address atrial fibrillation and venous thromboembolism in patients with myeloproliferative neoplasms (MPNs) is effective, with acceptable bleeding risk.
Ovarian cancer animation | Image Credit: Nuchjaree - stock.adobe.com
September 24th 2024

Olaparib/Cediranib Misses Survival End Points in Relapsed Ovarian Cancer Trial

Ashley Chan
Treatment with maintenance olaparib/cediranib demonstrated similar survival vs olaparib alone in platinum-sensitive relapsed ovarian cancer.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo